Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2013-12-20
AEs
1
Serious
0
Dropout signal
–
Adverse events
severe
assessed
Severe ATRIOVENTRICULAR BLOCK SECOND DEGREE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-18 (study day -2.0); relationship: NONE
Data queries
No data queries.